Bonus BioGroup Statistics
Total Valuation
Bonus BioGroup has a market cap or net worth of 189.91 million. The enterprise value is 192.65 million.
| Market Cap | 189.91M |
| Enterprise Value | 192.65M |
Important Dates
The next estimated earnings date is Monday, March 30, 2026.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.17B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 45.55% |
| Owned by Institutions (%) | 0.29% |
| Float | 635.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -382.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.44 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -35.31 |
Financial Position
The company has a current ratio of 0.21
| Current Ratio | 0.21 |
| Quick Ratio | 0.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.52 |
| Interest Coverage | -29.96 |
Financial Efficiency
Return on equity (ROE) is -371.95% and return on invested capital (ROIC) is -90.52%.
| Return on Equity (ROE) | -371.95% |
| Return on Assets (ROA) | -62.45% |
| Return on Invested Capital (ROIC) | -90.52% |
| Return on Capital Employed (ROCE) | -397.52% |
| Weighted Average Cost of Capital (WACC) | 8.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -204,678 |
| Employee Count | 37 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +328.57% in the last 52 weeks. The beta is 0.74, so Bonus BioGroup's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +328.57% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.17 |
| Relative Strength Index (RSI) | 66.57 |
| Average Volume (20 Days) | 10,990 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.32M |
| Pretax Income | -7.57M |
| Net Income | -7.57M |
| EBITDA | -6.84M |
| EBIT | -7.32M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 355,267 in cash and 2.85 million in debt, with a net cash position of -2.49 million.
| Cash & Cash Equivalents | 355,267 |
| Total Debt | 2.85M |
| Net Cash | -2.49M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -497,136 |
| Book Value Per Share | n/a |
| Working Capital | -2.61M |
Cash Flow
In the last 12 months, operating cash flow was -5.43 million and capital expenditures -24,337, giving a free cash flow of -5.46 million.
| Operating Cash Flow | -5.43M |
| Capital Expenditures | -24,337 |
| Free Cash Flow | -5.46M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bonus BioGroup does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.99% |
| FCF Yield | -2.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |